search
Back to results

Trabeculectomy With Ologen Collagen Implant vs Trabeculectomy With Provisc in Steroid Induced Glaucoma

Primary Purpose

Steroid Induced Glaucoma

Status
Completed
Phase
Phase 1
Locations
Azerbaijan
Study Type
Interventional
Intervention
Ologen Collagen Matrix
Provisc
Sponsored by
National Centre of Ophthalmology named after academician Zarifa Aliyeva
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Steroid Induced Glaucoma focused on measuring Trabeculectomy, Glaucoma, Steroids, Ologen, Viscoelastic

Eligibility Criteria

16 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age > 16 years (inclusive)
  • Patients with medically uncontrolled steroid induced glaucoma

Exclusion Criteria:

  • Primary open angle glaucoma, angle-closure glaucoma, post-traumatic, uveitic, neovascular, or dysgenetic glaucoma
  • Known allergic reaction to porcine collagen
  • Preliminary conjunctival damage (trauma, vitreo-retinal surgery, previous glaucoma or strabismus surgery, etc)

Sites / Locations

  • National Centre of Ophthalmology named after academician Zarifa Aliyeva

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Implantation of Ologen in trabeculectomy

Provisc in trabeculectomy

Arm Description

Ologen Collagen Matrix is implanted in primary limbal-based trabeculectomy. It should be placed on the top of the loosely-sutured scleral flap before suturing of the conjunctiva thus preventing the collapse of the subconjunctival space.

Provisc is used in primary limbal-based trabeculectomy. At the end of the surgery cohesive viscoelastic (Provisc) is injected under the scleral flap to prevent early hypotony.

Outcomes

Primary Outcome Measures

Intraocular Pressure (IOP)
The absolute success was defined as an IOP less than 21 mmHg with no glaucoma medications. Follow-up visits were and will arranged at 1 and 2 first weeks, then every month during first 6 months, then every 3 months during 2.5 years after surgery.

Secondary Outcome Measures

Postoperative complications
Complications were defined as follows: hypotony,shallow anterior chamber,serous or hemorrhagic choroidal detachment, hyphema,anterior chamber inflammation,persistent hypotonus maculopathy,corneal epithelial toxicity, "snuff" syndrome,blebitis or endophthalmitis,formation of Tenon's cyst.
Corrected distance visual acuity (CDVA)
Appearance of the filtering bleb (FB)

Full Information

First Posted
July 29, 2013
Last Updated
September 20, 2016
Sponsor
National Centre of Ophthalmology named after academician Zarifa Aliyeva
Collaborators
Aeon Astron Europe B.V.
search

1. Study Identification

Unique Protocol Identification Number
NCT01912638
Brief Title
Trabeculectomy With Ologen Collagen Implant vs Trabeculectomy With Provisc in Steroid Induced Glaucoma
Official Title
Comparative Study of the Efficacy and Safety of Ologen Collagen Implant Versus Cohesive Viscoelastic in Trabeculectomy Performed for Steroid Induced Glaucoma
Study Type
Interventional

2. Study Status

Record Verification Date
July 2015
Overall Recruitment Status
Completed
Study Start Date
July 2012 (undefined)
Primary Completion Date
September 2016 (Actual)
Study Completion Date
September 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Centre of Ophthalmology named after academician Zarifa Aliyeva
Collaborators
Aeon Astron Europe B.V.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this prospective randomized study is to assess and compare the clinical efficacy and safety of primary trabeculectomy with Ologen® collagen implant and cohesive viscoelastic (Provisc®) - augmented trabeculectomy in patients with medically uncontrolled steroid induced glaucoma.
Detailed Description
Steroid induced glaucoma is a well known and widely described disastrous clinical condition. However the subject of selection of most effective and safe treatment modality is still being discussed. Sihota R et al reported that 26.5% cases required surgical treatment to control IOP. Unfortunately survival rate of successful blebs in 10 years after trabeculectomy varies from 40% to 60%. Anti-fibrotic agent MMC as adjunct to filtration surgery was used to prevent postoperative scarring that could compromise surgical success of trabeculectomy. Additional use of MMC in trabeculectomy leads to low final IOP but could be associated with such complications as cataract formation, intraocular toxicity, avascular filtering blebs, wound leakage, subsequent blebitis and endophthalmitis. Tissue-engineered biodegradable and biocompatible implant Ologen® Collagen Matrix may be used as an alternative to MMC. Ologen® is CE Mark and FDA approved artificial porcine extracellular matrix for modulating wound healing. Ologen® has been tested in animal models and has triple action: prevent the collapse of the subconjunctival space; guides the fibroblast to grow through the matrix pores thus preventing scar formation; may act as an aqueous reservoir (avoids post-op hyperfiltration and shallow anterior chamber). The filtering blebs scoring was performed by using Moorfields Bleb Grading System and Visante anterior segment optical coherence tomography.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Steroid Induced Glaucoma
Keywords
Trabeculectomy, Glaucoma, Steroids, Ologen, Viscoelastic

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
17 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Implantation of Ologen in trabeculectomy
Arm Type
Experimental
Arm Description
Ologen Collagen Matrix is implanted in primary limbal-based trabeculectomy. It should be placed on the top of the loosely-sutured scleral flap before suturing of the conjunctiva thus preventing the collapse of the subconjunctival space.
Arm Title
Provisc in trabeculectomy
Arm Type
Active Comparator
Arm Description
Provisc is used in primary limbal-based trabeculectomy. At the end of the surgery cohesive viscoelastic (Provisc) is injected under the scleral flap to prevent early hypotony.
Intervention Type
Device
Intervention Name(s)
Ologen Collagen Matrix
Intervention Description
Ologen is a porous collagen-glycosaminoglycan matrix that decrease early postoperative scarring after penetrating anti-glaucomatous surgery by randomized collagen deposition and microcyst formation. Implantation of Ologen Collagen Matrix in trabeculectomy was performed.
Intervention Type
Drug
Intervention Name(s)
Provisc
Intervention Description
Provisc is an cohesive viscoelastic.
Primary Outcome Measure Information:
Title
Intraocular Pressure (IOP)
Description
The absolute success was defined as an IOP less than 21 mmHg with no glaucoma medications. Follow-up visits were and will arranged at 1 and 2 first weeks, then every month during first 6 months, then every 3 months during 2.5 years after surgery.
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Postoperative complications
Description
Complications were defined as follows: hypotony,shallow anterior chamber,serous or hemorrhagic choroidal detachment, hyphema,anterior chamber inflammation,persistent hypotonus maculopathy,corneal epithelial toxicity, "snuff" syndrome,blebitis or endophthalmitis,formation of Tenon's cyst.
Time Frame
2 years
Title
Corrected distance visual acuity (CDVA)
Time Frame
2 years
Title
Appearance of the filtering bleb (FB)
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age > 16 years (inclusive) Patients with medically uncontrolled steroid induced glaucoma Exclusion Criteria: Primary open angle glaucoma, angle-closure glaucoma, post-traumatic, uveitic, neovascular, or dysgenetic glaucoma Known allergic reaction to porcine collagen Preliminary conjunctival damage (trauma, vitreo-retinal surgery, previous glaucoma or strabismus surgery, etc)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Elmar Kasimov, Professor
Organizational Affiliation
Director of National Centre of Ophthalmology
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Fidan Aghayeva, MD
Organizational Affiliation
Glaucoma consultant at National Centre of Ophthalmology
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Centre of Ophthalmology named after academician Zarifa Aliyeva
City
Baku
ZIP/Postal Code
AZ1114
Country
Azerbaijan

12. IPD Sharing Statement

Learn more about this trial

Trabeculectomy With Ologen Collagen Implant vs Trabeculectomy With Provisc in Steroid Induced Glaucoma

We'll reach out to this number within 24 hrs